Cargando…

Altered systemic levels of acute phase proteins in tuberculous lymphadenitis and modulation after treatment

BACKGROUND: Pulmonary tuberculosis (PTB) is characterized by elevated levels of acute phase proteins (APPs), but their association with tuberculous lymphadenitis (TBL) is poorly studied. METHODS: We examined the systemic levels of APPs (alpha-2-macroglobulin [⍺-2MG], serum amyloid A [SAA], C-reactiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kathamuthu, Gokul Raj, Moideen, Kadar, Kumar, Nathella Pavan, Sridhar, Rathinam, Baskaran, Dhanaraj, Babu, Subash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259661/
https://www.ncbi.nlm.nih.gov/pubmed/32470023
http://dx.doi.org/10.1371/journal.pone.0233426
_version_ 1783540177781653504
author Kathamuthu, Gokul Raj
Moideen, Kadar
Kumar, Nathella Pavan
Sridhar, Rathinam
Baskaran, Dhanaraj
Babu, Subash
author_facet Kathamuthu, Gokul Raj
Moideen, Kadar
Kumar, Nathella Pavan
Sridhar, Rathinam
Baskaran, Dhanaraj
Babu, Subash
author_sort Kathamuthu, Gokul Raj
collection PubMed
description BACKGROUND: Pulmonary tuberculosis (PTB) is characterized by elevated levels of acute phase proteins (APPs), but their association with tuberculous lymphadenitis (TBL) is poorly studied. METHODS: We examined the systemic levels of APPs (alpha-2-macroglobulin [⍺-2MG], serum amyloid A [SAA], C-reactive protein [CRP] and haptoglobin [Hp]) in TBL, PTB, latent tuberculosis (LTB) and healthy controls (HC) at baseline and in TBL after the completion of anti-tuberculosis treatment (ATT). We have also examined the association of these proteins with lymph node (LN) size, culture grade and multiple versus single LN involvement. RESULTS: TBL individuals exhibited increased systemic levels of ⍺-2MG, SAA, CRP and Hp in comparison to HCs and increased CRP levels in comparison to LTB individuals. TBL individuals also exhibited decreased systemic levels of Hp compared to PTB individuals. APPs were not significantly associated with LN size, LN involvement and culture grade, indicating a lack of association with disease severity. Following ATT, post-treatment levels of ⍺-2MG, CRP and Hp were significantly diminished compared to pre-treatment levels. CONCLUSION: TBL disease is characterized by altered levels of APPs at baseline and modulated following treatment, indicating the presence of systemic inflammation.
format Online
Article
Text
id pubmed-7259661
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-72596612020-06-08 Altered systemic levels of acute phase proteins in tuberculous lymphadenitis and modulation after treatment Kathamuthu, Gokul Raj Moideen, Kadar Kumar, Nathella Pavan Sridhar, Rathinam Baskaran, Dhanaraj Babu, Subash PLoS One Research Article BACKGROUND: Pulmonary tuberculosis (PTB) is characterized by elevated levels of acute phase proteins (APPs), but their association with tuberculous lymphadenitis (TBL) is poorly studied. METHODS: We examined the systemic levels of APPs (alpha-2-macroglobulin [⍺-2MG], serum amyloid A [SAA], C-reactive protein [CRP] and haptoglobin [Hp]) in TBL, PTB, latent tuberculosis (LTB) and healthy controls (HC) at baseline and in TBL after the completion of anti-tuberculosis treatment (ATT). We have also examined the association of these proteins with lymph node (LN) size, culture grade and multiple versus single LN involvement. RESULTS: TBL individuals exhibited increased systemic levels of ⍺-2MG, SAA, CRP and Hp in comparison to HCs and increased CRP levels in comparison to LTB individuals. TBL individuals also exhibited decreased systemic levels of Hp compared to PTB individuals. APPs were not significantly associated with LN size, LN involvement and culture grade, indicating a lack of association with disease severity. Following ATT, post-treatment levels of ⍺-2MG, CRP and Hp were significantly diminished compared to pre-treatment levels. CONCLUSION: TBL disease is characterized by altered levels of APPs at baseline and modulated following treatment, indicating the presence of systemic inflammation. Public Library of Science 2020-05-29 /pmc/articles/PMC7259661/ /pubmed/32470023 http://dx.doi.org/10.1371/journal.pone.0233426 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Kathamuthu, Gokul Raj
Moideen, Kadar
Kumar, Nathella Pavan
Sridhar, Rathinam
Baskaran, Dhanaraj
Babu, Subash
Altered systemic levels of acute phase proteins in tuberculous lymphadenitis and modulation after treatment
title Altered systemic levels of acute phase proteins in tuberculous lymphadenitis and modulation after treatment
title_full Altered systemic levels of acute phase proteins in tuberculous lymphadenitis and modulation after treatment
title_fullStr Altered systemic levels of acute phase proteins in tuberculous lymphadenitis and modulation after treatment
title_full_unstemmed Altered systemic levels of acute phase proteins in tuberculous lymphadenitis and modulation after treatment
title_short Altered systemic levels of acute phase proteins in tuberculous lymphadenitis and modulation after treatment
title_sort altered systemic levels of acute phase proteins in tuberculous lymphadenitis and modulation after treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7259661/
https://www.ncbi.nlm.nih.gov/pubmed/32470023
http://dx.doi.org/10.1371/journal.pone.0233426
work_keys_str_mv AT kathamuthugokulraj alteredsystemiclevelsofacutephaseproteinsintuberculouslymphadenitisandmodulationaftertreatment
AT moideenkadar alteredsystemiclevelsofacutephaseproteinsintuberculouslymphadenitisandmodulationaftertreatment
AT kumarnathellapavan alteredsystemiclevelsofacutephaseproteinsintuberculouslymphadenitisandmodulationaftertreatment
AT sridharrathinam alteredsystemiclevelsofacutephaseproteinsintuberculouslymphadenitisandmodulationaftertreatment
AT baskarandhanaraj alteredsystemiclevelsofacutephaseproteinsintuberculouslymphadenitisandmodulationaftertreatment
AT babusubash alteredsystemiclevelsofacutephaseproteinsintuberculouslymphadenitisandmodulationaftertreatment